BR112017028137A2 - agente terapêutico para fibrose - Google Patents

agente terapêutico para fibrose

Info

Publication number
BR112017028137A2
BR112017028137A2 BR112017028137-6A BR112017028137A BR112017028137A2 BR 112017028137 A2 BR112017028137 A2 BR 112017028137A2 BR 112017028137 A BR112017028137 A BR 112017028137A BR 112017028137 A2 BR112017028137 A2 BR 112017028137A2
Authority
BR
Brazil
Prior art keywords
fibrosis
therapeutic agent
amino
therapeutic
thioxomethyl
Prior art date
Application number
BR112017028137-6A
Other languages
English (en)
Japanese (ja)
Other versions
BR112017028137B1 (pt
Inventor
Fujioka Akio
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of BR112017028137A2 publication Critical patent/BR112017028137A2/pt
Publication of BR112017028137B1 publication Critical patent/BR112017028137B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

são providos um agente terapêutico e uma composição farmacêutica que exercem um excelente efeito terapêutico ou profilático na fibrose e sintomas associados à fibrose. o agente terapêutico para fibrose compreende 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]-fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste como um ingrediente ativo
BR112017028137-6A 2015-06-25 2016-06-24 Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste BR112017028137B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-127788 2015-06-25
JP2015127788 2015-06-25
PCT/JP2016/068902 WO2016208744A1 (ja) 2015-06-25 2016-06-24 線維症治療剤

Publications (2)

Publication Number Publication Date
BR112017028137A2 true BR112017028137A2 (pt) 2018-08-28
BR112017028137B1 BR112017028137B1 (pt) 2023-04-04

Family

ID=57585165

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017028137-6A BR112017028137B1 (pt) 2015-06-25 2016-06-24 Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste

Country Status (21)

Country Link
US (4) US10449189B2 (pt)
EP (2) EP3973962A1 (pt)
JP (3) JP6974167B2 (pt)
KR (1) KR102647942B1 (pt)
CN (2) CN112716952A (pt)
AU (1) AU2016284531B2 (pt)
BR (1) BR112017028137B1 (pt)
CA (1) CA2990791A1 (pt)
DK (1) DK3315131T3 (pt)
ES (1) ES2928684T3 (pt)
HK (1) HK1245639A1 (pt)
HU (1) HUE060732T2 (pt)
MA (1) MA42266A (pt)
MX (2) MX2017016774A (pt)
MY (1) MY191219A (pt)
PH (1) PH12017502322A1 (pt)
PL (1) PL3315131T3 (pt)
PT (1) PT3315131T (pt)
RU (1) RU2729630C2 (pt)
SG (2) SG10201912684TA (pt)
WO (1) WO2016208744A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139608A1 (en) 2006-03-14 2007-12-06 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
EP3583943A4 (en) 2017-02-15 2020-12-30 Taiho Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION
EP3854395A4 (en) 2018-09-18 2022-06-15 Taiho Pharmaceutical Co., Ltd. COMBINATION THERAPY OF AN ACYLTHIOREA COMPOUND AND ABIRATERON
TW202140426A (zh) 2020-02-14 2021-11-01 日商大鵬藥品工業股份有限公司 醯基硫脲化合物的製造方法
CN115177636A (zh) * 2022-07-18 2022-10-14 陕西科美致尚生物科技有限公司 一种用于治疗前列腺钙化的组合物及其制备方法与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074264B1 (en) 1998-04-28 2008-09-17 Toshikazu Nakamura Neovascularization inhibitors
JP2003238592A (ja) * 2001-12-13 2003-08-27 Japan Tobacco Inc 組織及び血管の再生のための医薬及びその方法
AU2006265835B2 (en) 2005-06-30 2012-05-03 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
CN101360748B (zh) * 2005-11-30 2012-05-30 沃泰克斯药物股份有限公司 c-MET抑制剂及其应用
WO2007064797A2 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
CN101910158A (zh) 2007-10-25 2010-12-08 阿斯利康(瑞典)有限公司 可用于治疗细胞增殖性病症的吡啶衍生物和吡嗪衍生物
PT2287155E (pt) * 2008-04-10 2013-07-26 Taiho Pharmaceutical Co Ltd Composto de aciltioureia ou um seu sal, e sua utilização
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EP2531509B1 (en) * 2010-02-03 2016-10-05 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
DK2571878T3 (en) 2010-05-17 2019-02-11 Indian Incozen Therapeutics Pvt Ltd Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
RU2494470C1 (ru) * 2012-04-04 2013-09-27 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") Способ лечения фиброза легких
US9149471B2 (en) 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis

Also Published As

Publication number Publication date
KR102647942B1 (ko) 2024-03-14
SG11201709260TA (en) 2018-01-30
MA42266A (fr) 2018-05-02
MX2017016774A (es) 2018-05-14
CN107708697B (zh) 2021-02-09
US20200009128A1 (en) 2020-01-09
US20220047572A1 (en) 2022-02-17
EP3315131B1 (en) 2022-09-14
HK1245639A1 (zh) 2018-08-31
DK3315131T3 (da) 2022-11-14
MY191219A (en) 2022-06-09
AU2016284531B2 (en) 2020-06-04
US10695340B2 (en) 2020-06-30
BR112017028137B1 (pt) 2023-04-04
HUE060732T2 (hu) 2023-04-28
EP3973962A1 (en) 2022-03-30
PT3315131T (pt) 2022-10-26
CA2990791A1 (en) 2016-12-29
SG10201912684TA (en) 2020-03-30
EP3315131A1 (en) 2018-05-02
JP7258985B2 (ja) 2023-04-17
MX2020012989A (es) 2021-02-16
JPWO2016208744A1 (ja) 2018-04-12
PH12017502322A1 (en) 2018-06-25
ES2928684T3 (es) 2022-11-21
RU2017145271A (ru) 2019-07-25
JP6974167B2 (ja) 2021-12-01
CN112716952A (zh) 2021-04-30
JP2022009994A (ja) 2022-01-14
US20200297716A1 (en) 2020-09-24
PL3315131T3 (pl) 2022-12-12
US10449189B2 (en) 2019-10-22
JP7498827B2 (ja) 2024-06-12
EP3315131A4 (en) 2019-02-27
CN107708697A (zh) 2018-02-16
US11690838B2 (en) 2023-07-04
RU2017145271A3 (pt) 2019-12-02
US11191759B2 (en) 2021-12-07
JP2023076632A (ja) 2023-06-01
KR20180021682A (ko) 2018-03-05
US20180289690A1 (en) 2018-10-11
WO2016208744A1 (ja) 2016-12-29
RU2729630C2 (ru) 2020-08-11
AU2016284531A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
BR112018010018A2 (pt) moduladores de ror-gama
BR112016023422A8 (pt) dispersão seca por spray, composição farmacêutica e seus usos, kit e comprimido
BR112017028137A2 (pt) agente terapêutico para fibrose
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
DK3328843T3 (da) 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
WO2014153009A3 (en) Thiosaccharide mucolytic agents
BR112017003745A2 (pt) inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
BR112015001521A2 (pt) previsão de resposta ao tratamento para inibidor jak/stat
BR112016003584A8 (pt) composições farmaceuticas e uso das mesmas para regressão de placa acelerada
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112017028468A2 (pt) formulação sólida oral, e método para preparar uma formulação sólida oral
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
CO2019002245A2 (es) Combinación de agonistas de fxr
CL2019001550A1 (es) Fenytoina tópica para uso en el tratamiento del dolor neuropático periférico.
BR112019007543A2 (pt) inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase
EA201791716A1 (ru) Фармацевтический состав
BR112017016388A2 (pt) cenicriviroc para o tratamento da fibrose
BR112017001888A2 (pt) formulações biológicas para instilação intravesical
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
BR112019001134A2 (pt) uso de lactama e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/06/2016, OBSERVADAS AS CONDICOES LEGAIS